Phaseline

Companies › NeuroPace

NeuroPace: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RNS System
Closed-loop responsive brain stimulation device that detects abnormal electrical activity
–Phase 2EpilepsyNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05339126RNS SystemPhase 2EpilepsyNeurologyNov 2026

From the company's SEC filings

Cash and short-term investments of $52m on 2026-06-30; operating cash outflow about $20m a year; runway about 31 months at that burn, to Feb 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Nippon Shinyaku MED Institute Capricor Stoke Therapeutics Navamedic

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.